Biotechnology

NovelYeast is an R&D company with world-leading expertise in the design and development of superior industrial yeast strains. Our superior yeast strains for bioethanol and isobutanol production support the transition to a more sustainable bio-based economy in the sectors of automobile and aviation transport. Superior yeast strains for production of bio-based chemicals support reduction of […]

Geno.Me is a biotechnology company that was born from the idea of empowering people to take greater ownership of their health data, because it is a valuable and necessary asset to advance medical research. With a focus on creating better ways to treat populations that have diseases with a genetic predisposition, the organization allows people

IMUNOVA-EXPLORE THE MOST ADVANCED TECHNIQUES IN ANIMAL RESEARCH, ALONG WITH BIOTECHNOLOGICAL SOLUTIONS FOR PRODUCT DEVELOPMENT AND DIAGNOSTICS. Imunova: Pioneering Breakthroughs in Biotechnology for Animal Health Curitiba (Brazil)-based biotechnology firm, Imunova, is at the forefront of innovation in animal health, dedicated to testing and developing cutting edge products for the veterinary industry. Established in 2011 as

TransBIOTech, centre collégial de transfert en Biotechnologie, a été fondé en 1999 à la demande du Cégep de Lévis et s’appuie sur ses programmes techniques en biotechnologies et chimie analytique. Organisme à but non lucratif, TransBIOTech se spécialise en démonstrations d’efficacité et d’innocuité sur des composés actifs naturels destinés aux produits du mieuxêtre ou encore

Founded in 1999 at the request of the Cégep de Lévis, TransBIOTech is a college centre for biotech transfer that draws on the Cégep’s biotechnolog y and analytical chemistry technical programs. As a non-profit organization, we focus on demonstrating the efficacy and safety of natural active compounds for use in wellness products and of compounds

Readers of this publication know that Quebec is an incredibly fertile breeding ground for innovation. One of the reasons we generate so much innovation in Quebec is that we have mobilizing organizations in place that catalyze our expertise and knowledge. Among these organizations, the Québec Biotechnology Innovation Centre (QBIC) stands out. Created in 1996, QBIC

Les lecteurs de cette publication sont bien placés pour le savoir : le Québec est un terreau incroyablement fertile pour l’innovation. Si on génère autant d’innovations en sol québécois, c’est notamment parce que nous avons en place des organisations mobilisatrice qui catalyse notre expertise et notre savoir. Parmi ces organisations, le Centre québécois d’innovation en

Thus, the CÉPROCQ, early on, based its strategic priorities on green chemistry and sustainable development, which have now become essential to the growth of the industry. The CÉPROCQ is one of the few centers in Quebec, or even in Canada, to offer a research infrastructure on a pilot scale, thereby filling a gap in the

Grâce à ses liens avec les organisations issues de tous les maillons de la chaîne de valeur en sciences de la vie, BIOQuébec vous aide à explorer de nouvelles opportunités d’affaires et à entrer en relation avec les personnes-clés de l’écosystème québécois. Depuis 1991, l’association des biotechnologies et des sciences de la vie favorise la

The CRBM is recognized for its unique positioning as a transfer research organization in marine biotechnologies. With the investment of the Government of Quebec and Canada, completed by industrial contributions, the CRBM team leads projects framed by a solid scientific program oriented towards two research axes: health and well-being and the environment. The CRBM’s mission

La mission du CRBM est de supporter et de contribuer à la croissance de la filière des biotechnologies marines par des activités de recherche et développement scientifique et de transfert industriel, notamment pour le secteur des sciences de la vie.   Le CRBM est reconnu pour son positionnement unique comme centre d’innovation industrielle en biotechnologies

The key to innovation is seeing opportunity in unlikely places. For Antibe Therapeutics, the place is a cloud of noxious gas; the prize is a new generation of painkillers. In the wake of the opioid crisis, there is an urgent need for safer analgesics. Almost one-in-10 Canadians prescribed opioid medications report problematic use. Meanwhile, non-addictive

As the chairman of flanders.bio, an ex-CEO of four (4) start-up companies and an investor in the biotech scene in Europe, my heart and soul lie with Biotech. I have seen the Biotech landscape in Flanders grow to the absolute top in Europe. It is not without reason that the 2021 McKinsey study proclaimed Flanders